Daily Blood Test Could Help Sepsis Patients Stop Antibiotics Sooner

Intensive care doctors face a calculation that has no perfect answer: stop antibiotics too soon and risk a patient's death; continue them too long and you fuel the resistance that will make those drugs useless for everyone else. A new study from UK researchers suggests a way to tip that balance toward earlier stopping—a simple daily blood test that could shorten antibiotic courses in sepsis patients by nearly two days.

The research, led by teams at the University of Manchester and Northern Care Alliance NHS Foundation Trust, tracked 2,760 patients across 41 intensive care units and was published in the journal Anaesthesia. The trial, called ADAPT-Sepsis, tested whether automated guidance based on blood markers could help doctors make safer decisions about when to end treatment. The key finding: procalcitonin, a protein that rises during infection, prompted recommendations to stop antibiotics significantly earlier than C-reactive protein, another commonly monitored marker. Over more than 17,000 blood samples analyzed during the trial, procalcitonin-based guidance generated stop recommendations nearly two days sooner than CRP-based guidance—a substantial difference in a patient's total antibiotic exposure.

Sepsis itself is a medical emergency: the body's immune system overreacts to infection and begins attacking its own tissues, a cascade that kills thousands annually. Doctors treating sepsis patients are understandably reluctant to withdraw antibiotics. These are among the sickest people in the hospital, and the margin between recovery and death can feel impossibly thin. So patients often receive prolonged courses of powerful antibiotics, sometimes longer than necessary. But that caution carries its own cost. Unnecessary antibiotic use accelerates antimicrobial resistance—bacteria evolve defenses against the drugs meant to kill them—while also increasing side effects and straining healthcare budgets.

The trial revealed something subtle about how doctors actually work. Though physicians were more likely to follow recommendations based on CRP testing, those recommendations tended to align with existing practice and usually suggested continuing treatment as usual. Procalcitonin offered something different: earlier signals that treatment could safely end. The researchers found that doctors most often ignored stop recommendations when microbiology guidance called for fixed treatment durations, or when patients still showed signs of severe illness, persistent fever, or elevated inflammation markers. In other words, the blood test was speaking, but clinical judgment and caution were speaking louder.

Paul Dark, the study's principal investigator and a professor of critical care medicine, framed the dilemma plainly: intensive care doctors have spent decades managing an impossible balance. "Nobody wants to stop antibiotics too early and risk a patient's life, but continuing them unnecessarily also carries real dangers for individuals and society," he said. The blood test, he suggested, could provide an additional layer of reassurance—not a replacement for clinical judgment, but a tool to help doctors feel confident acting on what the numbers show.

The path forward depends on implementation. The researchers emphasize that procalcitonin-guided stewardship would need to work alongside existing clinical frameworks and microbiology protocols, not replace them. Hospitals would need to build confidence among their teams that the biomarker guidance is trustworthy enough to act on. The stakes are global: antimicrobial resistance is a growing threat that affects treatment options for infections everywhere. A simple daily blood test that safely reduces antibiotic exposure in the sickest patients could preserve the effectiveness of these drugs for future generations. But only if clinicians believe in it enough to change their practice.